-
The Unified Dyskinesia Rating Scale (UDysRS): Clinimetric Testing Program
… of daily living, and the patient’s perception of disability from dyskinesias. The scale has been tested in preliminary … Foundation grant, in conjunction with additional funding from Merck KaA/EMD Pharmaceutical, will support the phases …
-
Ability to Slow Disease Progression and Safety and Tolerability of Green Tea Polyphenols in Early Parkinson’s Disease
… were treated for 12 months. The change in total UPDRS score from randomization to six months was significantly improved … 12 months. In the delayed-start group, the change in UPDRS from six months (the start of active GTP) to 12 months was …
-
Normal Role of Synuclein in Mitochondrial Bioenergetics at the Synapse
… can compensate when alpha-synuclein is lost. Our data from preclinical models thus suggests that therapeutic … reduction of alpha-synuclein levels will be safe from a mitochondrial perspective. …
-
Evaluation of mGlu4 Positive Allosteric Modulators in Models of Parkinson’s Disease
… symptoms using a clinical rating scale that is adapted from the scale used to assess disability in PD patients. … need for a clinical trial. Overall, the results from this study have validated mGlu4 PAM activity in a …
-
Age-related Alterations in LRRK2 Expression and Function in Immune Cells and Risk for Idiopathic Parkinson's Disease
… Project Description: Immune cell subtypes will be isolated from peripheral blood idiopathic PD patients and of age- and … in LRRK2 levels in immune cell subsets and/or uncoupling from key immune cell signaling pathways that dysregulate …
-
[18F]flubatine: A Novel Biomarker of Cognition in Parkinson's Disease
… to identify those patients who are expected to benefit most from nicotinic receptor drug treatment. Final Outcome Mild … identify those individuals who are more likely to benefit from such therapy. …